This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): TNX-100, 5D12
Description: Antibodies targeting CD40 on the surface of B cells have the potential to block B cell responses, and thus dampen autoimmune responses.
TNX-100 is similar to IDEC-131, also an anti-CD40 ligand antibody.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Tanox licensed this antibody from a Dutch subsidiary of Chiron.
In August 2007, Genentech completed the acquisition of Tanox.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
Partners: Novartis AG
Pink Sheet ICAAC In Brief
Additional information available to subscribers only: